Products Affected - Description
PhosLo capsules, Fresenius Medical
667 mg capsules, 200 count (NDC 49230-0640-21)
Reason for the Shortage
- Fresenius Medical cannot provide a reason for the shortage.
- Hawthorne states the reason for the shortage was manufacturing delay.
Eliphos tablets, Hawthorne Pharmaceuticals
667 mg tablets, 200 count (NDC 63717-0910-02)
Calcium acetate capsules, Camber Pharmaceuticals
667 mg capsules, 200 count (NDC 31722-0377-02)
Calcium acetate tablets, Perrigo
667 mg tablets, 200 count (NDC 00574-0113-02)
Calcium acetate capsules, Roxane
667 mg capsules, 200 count (NDC 00054-0088-26)
Calcium acetate capsules, Sandoz
667 mg capsules, 200 count (NDC 00781-2081-02)
Estimated Resupply Dates
- Fresenius Medical has PhosLo capsules on back order and the company cannot estimate a release date.
- All generic products have been readily available for several months. This shortage is resolved.
July 7, April 15, January 26, 2015; December 3, September 10, June 16, April 11, March 6 and 17, February 24, 2014; December 6, October 31, September 25, August 5, June 6 and 27, May 20, March 12, February 13, January 8, 2013; December 10, September 27, July 9, May 1 and 21, April 11, March 8 and 30, February 21, and January 19 and 31, 2012; December 21, December 8, November 18, October 4, 12, and 26, September 7, 16, and 30, August 26, August 15, 2011. University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins